Download Wegovy Savings Card

If you have private or commercial insurance with coverage, you may pay as little as $0 per 28-day supply (1 box) of Wegovy subject to a maximum savings of $225 per 28-day supply (1 box) for up to 13 fills. If you pay cash for your prescriptions or your commercial insurance does not cover Wegovy, you can save up to $500 per 28-day supply (1 box) of Wegovy.a

*Subject to maximum savings of $225 per 28-day supply (1 box) for up to 12 fills for commercially insured patients with Wegovy coverage. Patients with commercial insurance who do not have coverage for Wegovy, can save $500 per 28-day supply (1 box). Offer must be activated by 12/31/23. Eligibility and other restrictions apply, see WegovyTerms.com for details. Novo Nordisk reserves the right to modify or cancel the program at any time.

Download Zip 🔥 https://urlin.us/2y4Ox2 🔥

If you have commercial insurance, and your doctor prescribes this medicine, it may be more affordable to gain access with a Wegovy Savings Copay Card supplied from Novo Nordisk, the manufacturer. Eligible commercially insured patients may pay as little as $25 per 28 day supply (1 box of injectable pens) with a maximum savings of $200 per prescription fill. Copay cards are not typically eligible to patients with government sponsored insurance such as Medicare, Medicaid or TriCare.

Consumers using the ScriptSave WellRx savings program can expect average savings of 65% and, in some cases, it can be 80% or more* on brand and generic prescription drugs - that's instant savings at the register for your whole family. Just follow these 3 easy steps to start saving today!

A recent late-stage trial found that Wegovy reduced the risk of cardiovascular events such as heart attack and stroke by 20%. The results suggest that Wegovy and similar obesity and diabetes medications like those in development by Eli Lilly and others could have long-lasting health benefits beyond shedding unwanted pounds.

*FOR THERAPEUTIC ALTERNATIVES: Therapeutic alternatives may be appropriate to treat the same condition as your current drug treats; prices and savings shown are estimates. Your health care provider will determine whether a particular therapy is appropriate for you and your condition.

*FOR ENCOURAGING MEDICATION ADHERENCE: Rymer J, Fonseca E, Bhandary D, et al. Difference in medication adherence between patients filling 30 versus 90 day prescription supply after acute myocardial infarction. Journal of American College of Cardiology. 2018; 71:69.

Semaglutide causes thyroid C-cell tumors in rodents at clinically relevant levels. It is not known if wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.

Wegovy is the trademark brand name for semaglutide manufactured by Novo Nordisk, Inc. A generic version of semaglutide is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Wegovy savings through NiceRx.

DISCLAIMER: NiceRx is a conduit between consumers in need of prescription drug savings. NiceRx is not affiliated or contracted with any of the pharmaceutical companies or products which are illustrated on this website. NiceRx is not compensated in any capacity by any of the manufacturers. All of the information about prescription drugs on this website has not been provided to NiceRx by the manufacturer.

Novo Nordisk's Wegovy cut the risk of serious cardiovascular complications in people with obesity and heart disease in a closely watched trial, demonstrating a particularly large effect on heart attacks, a promising new frontier for the drug.

The roughly 17,500-person Select study tested Wegovy in people with obesity and heart disease but who did not have diabetes. Weekly injections of Wegovy slashed the overall risk of heart attack, stroke and death from cardiovascular causes by 20%, according to detailed results from the trial presented Saturday at the American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine. Novo Nordisk disclosed topline data from the study in August.

The new data could also help the Danish pharmaceutical company maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was approved in the U.S. earlier this week. Zepbound has been shown to help people lose more weight, but it hasn't yet demonstrated an effect on cardiovascular outcomes.

"If you look at where the insurance companies are going to be obliged to go, they're going to be obliged to go with the drug that reduces cardiovascular events," said Dr. Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart who was involved with the study.

What's more, Wegovy started to show a reduction in overall cardiovascular events within months of participants starting the drug, with the difference between the drug and placebo widening as the study continued. Researchers observed that effect even before people lost significant weight, a "fascinating" finding that suggests both weight loss and the drug itself could be playing a role in heart health, said Dr. Ania Jastreboff, director of the Yale Obesity Research Center.

Almost 17% of people receiving Wegovy in the trial stopped taking the drug, mainly because of gastrointestinal issues like vomiting and diarrhea, double the rate of people who discontinued the placebo. But more people in the control group experienced serious adverse events such as cardiac disorders and medical procedures.

Seeing a diabetes drug producing positive cardiovascular and metabolic effects "opens a new door to treat obese patients with cardiovascular disease," said Dr. George Dangas, director of cardiovascular innovation for Mount Sinai Hospital. But it could take time and energy to incorporate it into clinical practice.

To lower your out-of-pocket cost for Wegovy, you can get Wegovy covered by insurance (usually, with prior authorization). Novo Nordisk also offers a Wegovy savings card. If Wegovy is covered by your insurance plan, you can save up to $200 per 28-day supply. If it is not covered by your insurance plan, you can save up to $500 per 28-day supply.

People who have health insurance and who live in the US may qualify for the Wegovy savings card, which covers up to six 28-day fills (four injectable pens) of the medication. With the card, you may pay as little as $0 per month for your Wegovy prescription.

For those with commercial insurance coverage, your copay may be reduced to as little as $0 per month for up to 12 fills, with maximum savings of $225 per 28-day supply. Patients with commercial insurance who do not have coverage for Wegovy or patients paying cash with non-government insurance, can save $500 per 28-day supply.

Our website gives savings options to customers who wish to purchase WEGOVY, as either a brand or generic, without the constraints of insurance. By using the Rx Advantage Card, users can save up to 90% on the cost of their medication. The card can be used at over 65,000 pharmacies nationwide, across America. Even if you are insured, in most cases the cash price will be significantly cheaper than your existing co-pay. NowPatient is able to negotiate discounts on bulk drug purchases with pharmacy owners meaning you can access lower medication prices at nearby pharmacies using our card that can be conveniently stored in your NowPatient account.

You can search for the prices at nearby pharmacies using our website. Simply search your medication and enter your ZIP Code and we will show you the price of your drug at nearby pharmacies. If you are happy with the quote, you need to create an account with NowPatient and generate your card. Next, simply go to the pharmacy and fill your WEGOVY Rx. Ask the pharmacy to run the card and check the price, even if they tell you they have another card they use. Your card is stored safely in your NowPatient account.

You can check the top of the page to see if there is an option for a WEGOVY co-pay card. Co-pay cards are programs run by pharmaceutical companies that offer you a direct way to lower your out-of-pocket costs for prescription drugs for eligible patients. The copay cards essentially allow physicians to prescribe medications that are clinically preferred.

Most likely, no. The copay card program is primarily designed for commercially or privately insured individuals. However, if you are finding it difficult to afford your medication, then there are other forms of assistance. For example, you can apply for LIS (Low Income Subsidy) or extra help is available online at SSA Medicare D Extra Help. You can also call Social Security at 1-800-772-1213 (TTY 1-800-325-0778). As well, you can look at state assistance programs like Medicaid.

If a WEGOVY co-pay card exists, you will see it as a savings option at the top of the page. You can select the option and it will direct you to an eligibility checker. If you qualify you will be prompted to create an account with NowPatient, from where you will be able to access the instructions on how to enroll.

Once you are enrolled into the program you will be able to download the card. When you next fill your Rx, simply present the co-pay card to the pharmacist. The Pharmacist will use the card to process and submit your claim. You will then be provided with your discount. The program cost is covered by the pharmaceutical company.

If a WEGOVY patient assistance program exists, you will see it as a savings option at the top of the page. You can select the option and it will direct you to an eligibility checker. If you qualify you will be prompted to create an account with NowPatient, from where you will be able to access the instructions on how to enroll. e24fc04721